BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25232060)

  • 21. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
    Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
    Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging targeted therapies in myelofibrosis.
    Barosi G
    Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving treatment paradigm in myelofibrosis.
    Mesa RA
    Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
    Sastow D; Mascarenhas J; Tremblay D
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the management of myelofibrosis.
    Komrokji RS; Verstovsek S; Padron E; List AF
    Cancer Control; 2012 Oct; 19(4 Suppl):4-15. PubMed ID: 23042420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.